1Q EARNINGS: Lilly sales sink as growth floats to 2015
This article was originally published in Scrip
Eli Lilly didn't goose its latest earnings report or quack about successes outside of commercial activities to divert attention from the company's expected sales slump, but Lilly is getting its research and business development ducks in a row to ensure growth in 2015.
You may also be interested in...
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.